When KRAS mutations, which are found in 30–40% of CRC patients, are present, these pathways are activated continuously, which makes anti-EGFR monoclonal antibodies less effective in blocking EGFR [10,11,12,13]. This evidence concerns the gene KRAS and colorectal carcinoma.